

IMPACT FACTOR 4.5





an Open Access Journal by MDPI

Mechanisms of Immunosuppression in Cancer

Guest Editor:

Dr. Shweta Joshi

Department of Pediatrics, Moores Cancer Center, University of California, San Diego, CA, USA

Deadline for manuscript submissions:

closed (30 December 2023)

Message from the Guest Editor

Tumor-induced immunosuppression hampers and modulates the activity of cytotoxic T cells and NK cells through the secretion of various cytokines and metabolites, and recruitment of immunosuppressive cells such as myeloid-derived suppressor cells, tumor-associated macrophages, regulatory T cells, and regulatory B cells. Hence, it is crucial to understand various tumor-induced immunosuppressive mechanisms to design and develop effective novel immunotherapies and to refine approaches to improve currently available immunotherapies.

This Special Issue invites original research articles and review articles to address the mechanisms of tumor-induced immunosuppression, major impediments for effective antitumor immunity, and approaches to convert 'cold tumors' into 'hot tumors', which are focused on but not limited to the reprogramming of immune cells, novel immune checkpoints, normalizing tumor vasculature, cytokine modulation, metabolic intervention, targeting exosomes, and strategies to block the infiltration of immunosuppressive cells in the tumor bed.













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us